methyl brevifolincarboxylate: isolated from Phyllanthus urinaria; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
methyl brevifolincarboxylate : An organic heterotricyclic compound that is 1,2,3,5-tetrahydrocyclopenta[c]isochromene substituted by hydroxy groups at positions 7, 8 and 9, oxo groups at positions 3 and 5 and a methoxycarbonyl group at position 1. Isolated from Phyllanthus urinaria and Phyllanthus niruri, it exhibits vasorelaxant activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Niruri | genus | [no description available] | Euphorbiaceae | The spurge family of flowering plants in the order Malpighiales. The family consists of annual and perennial herbs and woody shrubs or trees. Members contain securinine.[MeSH] |
| Phyllanthus | genus | A plant genus of the family EUPHORBIACEAE. Bahupatra (MEDICINE, AYURVEDIC) is prepared from this.[MeSH] | Phyllanthaceae | [no description available] |
| Phyllanthus niruri | species | [no description available] | Phyllanthaceae | [no description available] |
| Phyllanthus urinaria | species | [no description available] | Phyllanthaceae | [no description available] |
| ID Source | ID |
|---|---|
| PubMed CID | 5319518 |
| CHEMBL ID | 567076 |
| CHEBI ID | 66711 |
| MeSH ID | M0232441 |
| Synonym |
|---|
| methyl brevifolincarboxylate |
| chebi:66711 , |
| CHEMBL567076 , |
| methylbrevifolin carboxylate |
| methyl 7,8,9-trihydroxy-3,5-dioxo-1,2-dihydrocyclopenta[c]isochromene-1-carboxylate |
| 154702-76-8 |
| methyl 7,8,9-trihydroxy-3,5-dioxo-1,2,3,5-tetrahydrocyclopenta[c]isochromene-1-carboxylate |
| bdbm50415047 |
| Q27135333 |
| DTXSID20935047 |
| methyl 7,8,9-trihydroxy-3,5-dioxo-1,2,3,5-tetrahydrobenzo[d]cyclopenta[b]pyran-1-carboxylate |
| CS-0134956 |
| AKOS040755436 |
| HY-N7647 |
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| vasodilator agent | A drug used to cause dilation of the blood vessels. |
| EC 5.99.1.2 (DNA topoisomerase) inhibitor | A topoisomerase inhibitor that inhibits the bacterial enzymes of the DNA topoisomerases, Type I class (EC 5.99.1.2) that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. These bacterial enzymes reduce the topological stress in the DNA structure by relaxing negatively, but not positively, supercoiled DNA. |
| EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | A topoisomerase inhibitor that inhibits DNA topoisomerase (ATP-hydrolysing), EC 5.99.1.3 (also known as topoisomerase II and as DNA gyrase), which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. |
| radical scavenger | A role played by a substance that can react readily with, and thereby eliminate, radicals. |
| platelet aggregation inhibitor | A drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| organic heterotricyclic compound | An organic tricyclic compound in which at least one of the rings of the tricyclic skeleton contains one or more heteroatoms. |
| delta-lactone | A lactone having a six-membered lactone ring. |
| phenols | Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring. |
| cyclic ketone | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Triosephosphate isomerase, glycosomal | Trypanosoma cruzi | IC50 (µMol) | 6.5000 | 1.2000 | 3.8500 | 6.5000 | AID445517 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| gluconeogenesis | Triosephosphate isomerase | Homo sapiens (human) |
| methylglyoxal biosynthetic process | Triosephosphate isomerase | Homo sapiens (human) |
| glyceraldehyde-3-phosphate biosynthetic process | Triosephosphate isomerase | Homo sapiens (human) |
| canonical glycolysis | Triosephosphate isomerase | Homo sapiens (human) |
| glycolytic process | Triosephosphate isomerase | Homo sapiens (human) |
| glycerol catabolic process | Triosephosphate isomerase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| triose-phosphate isomerase activity | Triosephosphate isomerase | Homo sapiens (human) |
| protein binding | Triosephosphate isomerase | Homo sapiens (human) |
| methylglyoxal synthase activity | Triosephosphate isomerase | Homo sapiens (human) |
| ubiquitin protein ligase binding | Triosephosphate isomerase | Homo sapiens (human) |
| protein homodimerization activity | Triosephosphate isomerase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular space | Triosephosphate isomerase | Homo sapiens (human) |
| nucleus | Triosephosphate isomerase | Homo sapiens (human) |
| cytosol | Triosephosphate isomerase | Homo sapiens (human) |
| extracellular exosome | Triosephosphate isomerase | Homo sapiens (human) |
| cytosol | Triosephosphate isomerase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1494600 | Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pretreated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 mins by spectrophotomet | 2018 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9 | Anticomplement compounds from Polygonum chinense. |
| AID445517 | Inhibition of Trypanosoma cruzi recombinant triosephosphate isomerase after 2 hrs | 2009 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20 | Selective inactivation of triosephosphate isomerase from Trypanosoma cruzi by brevifolin carboxylate derivatives isolated from Geranium bellum Rose. |
| AID445518 | Inhibition of human recombinant triosephosphate isomerase after 2 hrs | 2009 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20 | Selective inactivation of triosephosphate isomerase from Trypanosoma cruzi by brevifolin carboxylate derivatives isolated from Geranium bellum Rose. |
| AID1494599 | Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pretreated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometeric me | 2018 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9 | Anticomplement compounds from Polygonum chinense. |
| AID445519 | Binding affinity to Trypanosoma cruzi recombinant triosephosphate isomerase | 2009 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20 | Selective inactivation of triosephosphate isomerase from Trypanosoma cruzi by brevifolin carboxylate derivatives isolated from Geranium bellum Rose. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.39) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||